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A number of important findings have recently emerged relevant to identifying genetic risk 
factors for schizophrenia. Findings using common variants point towards gene sets of 
interest and also demonstrate an overlap with other psychiatric and non-psychiatric 
disorders. Imputation of variants of the gene for complement component 4, C4, from GWAS 
data has shown that the predicted expression of the C4A product is associated with 
schizophrenia risk. Very rare variants disrupting SETD1A, RBM12 or NRXN1 have a large 
effect on risk. Other rare, damaging variants are enriched in genes which are loss of function 
intolerant and/or whose products localise to the synapse. These and particular copy number 
variants (CNVs) can result in increased risk of schizophrenia but also of other 
neurodevelopmental disorders. The findings for C4 and for NRXN1 may be especially helpful 
for elucidating the biological mechanisms which can lead to disease. 
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Introduction 
Research into the genetics of schizophrenia is advancing rapidly and several important 
findings have emerged since the comprehensive review by Harrison in 2015 (Harrison 
2015). At that time, a large GWAS carried out by the Psychiatric Genomics Consortium 
(PGC) had just been published which implicated over 100 loci at genome-wide significance, 
all with small effect sizes (Schizophrenia Working Group of the Psychiatric Genomics 
Consortium 2014). Associations were enriched for genes expressed in the brain and in 
tissues with important roles in immunity. This study demonstrated that the cumulative effect 
of common variants could not explain the observed high heritability of schizophrenia and the 
problem of the “missing heritability” remained (Harrison 2015). The present article aims to 
provide a brief summary of more recent findings in order for the non-specialist to gain an 
overview of where the field currently stands. We present findings for individual genes, for 
common and rare variants and for copy number variants. We also present some results 
regarding the genetic relationship between schizophrenia and other disorders, notably 
developmental disability. 
Findings for individual genes 
The first specific gene to be implicated in the aetiology of schizophrenia was DISC1, when it 
was shown that a balanced translocation disrupting this gene cosegregated with 
schizophrenia and other psychiatric diagnoses in an extended pedigree from Scotland (Millar 
et al. 2000). However it has since proved difficult to elucidate the mechanism of this effect or 
to conclusively link other variants in this gene to increased risk (Wang et al. 2018). Although 
the 2014 GWAS produced a number of hits in or near genes of interest, it did not implicate 
any specific variants which clearly had a direct functional effect (Schizophrenia Working 
Group of the Psychiatric Genomics Consortium 2014). Since then, evidence has emerged 
which provides a handful of examples where effects can be ascribed to particular types of 
variant affecting particular genes, comprising complement component 4 (C4), neurexin 1 
(NRXN1), RNA-binding motif 12 (RBM12) and SETD1A.  
The most significant GWAS hit occurred in the major histocompatibility (MHC) locus, which 
had been consistently implicated as associated with schizophrenia in a number of previous 
studies (Harrison 2015). However, identifying the gene or genes driving this signal had 
proved problematic, partly because of the complex and long range linkage disequilibrium 
(LD) relationships which are observed in this region. Using droplet digital PCR (ddPCR), 
Sekar and colleagues characterised complex variation in C4, the gene coding for 
complement component 4 (Sekar et al. 2016). Three kinds of variation commonly exist: the 
total number of copies can vary between 0 and 5; each copy can be long or short (L or S), 
depending on whether or not it contains a HERV insertion; each copy may be either of two 
paralogous genes (isotypes) which are denoted C4A and C4B and whose products bind 
different molecular targets. Four structural forms of C4A/C4B are commonly observed (BS, 
AL–BS, AL–BL, and AL–AL) and each of these was shown to be associated with differing 
levels of expression and each could be reliably imputed using the SNPs from the GWAS. 
This made it possible to use the PGC sample of 28,799 schizophrenia cases and 35,986 
controls to show that predicted C4A expression from imputed C4 variants was associated 
with schizophrenia risk (p = 3.6 x 10-24) (Sekar et al. 2016). In a smaller number of subjects 
they confirmed that directly measured C4A expression was indeed higher in schizophrenia 
cases. The authors also demonstrated that C4A is present on neurons and synapses and 
they postulated that increased expression could lead to increased synaptic pruning, which 
would produce the smaller number of synapses which have been observed in patients with 
schizophrenia. They demonstrated that mice deficient in C4 showed changes consistent with 
reduced synaptic pruning. Although the effect on schizophrenia risk is only moderate, with 
OR of 1.3 between the structural forms with highest and lowest risk, this important paper is 
the first to link genetic variants to clear changes in function which impact in a biologically 
meaningful way. 
In a genome-wide analysis of copy number variants (CNVs), eight loci were individually 
genome-wide significant, including a deletion at 2p16.3 (OR=5.9, p = 4.9 x 10-9)  (Marshall et 
al. 2016). This is of especial interest because the deletion varies in size and is in some 
cases so small that it only effects exons of a single gene, NRXN1, which codes for neurexin 
1. This result is aligned with previous reports that deletions of NRXN1 were associated with 
schizophrenia and other developmental disorders (Rujescu et al. 2009; Ching et al. 2010). 
Neurexins mediate synaptic function and mice in which NRXN1 is deleted have impaired 
social memory (Dachtler et al. 2015). Thus, there now seems to be good evidence that loss 
of one copy of NRXN1 can substantially increase the risk of schizophrenia and this suggests 
that abnormal synaptic functioning may form part of the pathophysiology. 
A study of an Icelandic family containing ten subjects with a psychiatric disorder, of whom six 
had a diagnosis of schizophrenia, revealed that all subjects with psychosis had a single 
nonsense mutation in RNA-Binding Motif 12 (RBM12) that was carried by all individuals with 
psychosis (Steinberg et al. 2017). The authors performed an extensive search in an attempt 
to find other subjects with variants disrupting RBM12 and were able to identify a Finnish 
case with schizophrenia who had a different truncating variant in this gene, c.2532delT. This 
subject was found to have four siblings with psychosis who all carried the same variant. 
Thus, it seems that truncating mutations of RBM12 can substantially increase the risk of 
schizophrenia. However these are extremely rare and at time of writing very little is known 
about the biological function of this gene.  
Earlier studies had provided some evidence that loss of function (LoF) variants affecting 
SETD1A were associated with schizophrenia (Takata et al. 2014; Fromer et al. 2014). These 
were followed up in a whole exome sequenced sample containing 4,264 schizophrenia 
cases, 9,343 controls and 1,077 trios (cases with schizophrenia and their parents) (Singh et 
al. 2016). A combined case-control and de novo mutation analysis confirmed the association 
of SETD1A LoF variants with schizophrenia (p = 3.3 x 10-9). In a follow-up investigation of 
over 20,000 exomes, 10 LoF additional variants were identified in cases and none in 
controls. Out of 45,376 exomes in ExAC, only two were found to have SETD1A LoF variants. 
Examination of an exome-sequenced sample of 3,148 children with diverse, severe 
developmental disorders revealed that four had LoF variants in SETD1A and a fifth had a de 
novo deletion which included it. Overall, this study provided strong evidence that these very 
rare variants can have a substantial effect on increasing risk of schizophrenia or 
developmental disorder. SETD1A codes for a component of a histone methyl transferase 
and disruption of its function might be expected to have effects on the expression of many 
other genes. Thus, this finding does not immediately provide clear insights relating genetic 
variation to relevant biological functionality. 
Common variants 
A recent GWAS using a Chinese cohort consisting of 12,083 schizophrenia cases and 
24,097 controls identified 7 loci associated to schizophrenia, 4 of which were novel, and 
when a subset of this cohort was analysed in combination with the PGC GWAS a total of 30 
novel loci were found with genome wide significance (Li et al. 2017). The authors used 
factors such as proximity, missense mutations and expression quantitative locus information 
to highlight 247 genes, of which 85 could be defined as "prioritized candidate genes". 
However, none can be conclusively declared to be involved in disease causation. 
A major emphasis of studies of common variants has been not only to search for SNPs 
associated with schizophrenia risk but also to investigate relationships with the genetic 
susceptibility to different outcomes. Methods such as the polygenic risk score (PRS) and LD-
regression aim to detect an overlap of multiple common variants associated with different 
phenotypes even if variants are not individually statistically significant. A recent review of the 
application of PRS analysis to schizophrenia identified 31 articles examining association with 
another phenotype (Mistry et al. 2017). There seems to be some overlap of common genetic 
risk factors for schizophrenia with other psychiatric disorders, notably depression, bipolar 
disorder and borderline personality disorder (Cross-Disorder Group of the Psychiatric 
Genomics Consortium 2013; Lee et al. 2013; Witt et al. 2017). There are also results 
suggesting that the polygenic contribution to schizophrenia risk is associated with poorer 
cognitive functioning and a number of non-psychiatric conditions including diabetes, 
rheumatoid arthritis, Crohn's disease and amyotrophic lateral sclerosis (McIntosh et al. 2013; 
Hubbard et al. 2016; Stringer et al. 2014; McLaughlin et al. 2017). 
Rare variants 
A study of a whole exome sequenced Swedish sample of 4,877 cases and 7,455 controls 
focussed on damaging ultra-rare variants (dURVs), defined as nonsense, frame-shift and 
splice site variants found in only a single subject and absent from ExAC (Purcell et al. 2014; 
Lek et al. 2016). Although no individual genes were implicated, dURVs were enriched 
among cases in a number of gene sets, some overlapping each other, including genes near 
GWAS hits, genes known to cause intellectual disability, neuron specific genes, genes 
whose mRNAs are bound by fragile X mental retardation protein (FMRP) and genes 
encoding interactors with PSD-95, ARC, and NMDA receptors (Genovese et al. 2016). 
These results conclusively demonstrated that rare variants contribute to schizophrenia 
pathogenesis. They also point towards some of the biological processes likely to be 
involved. 
Rare variants were also investigated in a UK cohort consisting of 5,585 schizophrenia cases 
and 8,103 controls. Only uncommon variants with minor allele frequency (MAF) < 1% were 
considered. No variant or gene was found to reach genome wide significance, and the only 
gene set to reach an adjusted significance threshold was that consisting of FMRP targets 
(which tend to be localised to the synapse) (Richards et al. 2016). A study combining the 
Swedish cohort and UK cohorts, including a total of 10,011 schizophrenia cases and 13,791 
controls, demonstrated enrichment of rare variants in two gene sets, targets of FMRP and 
genes which are loss of function intolerant (Leonenko et al. 2017). One variant in MCPH1, 
rs61749465, approached but failed to reach exome-wide significance, a result possibly of 
interest because mutations in this gene are associated with primary autosomal recessive 
microcephaly. 
Copy number variants 
CNVs have been strongly implicated in schizophrenia risk, as previously reviewed (Harrison 
2015). A large collaborative study, incorporating 43 separate datasets, included 21,094 
schizophrenia cases compared to 20,227 controls  (Marshall et al. 2016). In this sample, the 
CNV burden was increased in cases even after removing previously implicated loci (OR = 
1.07, p = 1.7 x 10-6). There was a larger enrichment for copy number losses than copy 
number gains (ORLoss = 1.4, pLoss = 4 x 10-16; ORGain = 1.1, pGain = 2 x 10-7). This study  
implicated 8 CNV loci which were individually genome wide significant, including the NRXN1 
deletion referred to above.  
36 gene sets were tested for CNV burden, of which 15 were significantly enriched for rare 
copy number losses, where the gene set “GO synaptic” was ranked the most statistically 
significant (p = 2.8 x 10-11) and the gene set “ARC complex” was found to have the largest 
effect size (OR > 1.8). NMDA receptor complex genes, brain expressed genes and 
prenatally expressed brain genes were significantly enriched for duplications (Marshall et al. 
2016).  
A study of CNVs identified associated with schizophrenia demonstrated that although they 
had a substantial effect on risk of schizophrenia they were in fact more likely to result in 
other phenotypes, consisting of developmental disorder (DD), autism spectrum disorder 
(ASD) and congenital malformations (CM) (Kirov et al. 2014). Thus, for the NRXN1 and the 
22q11.21 deletions the estimated penetrance values for schizophrenia were 0.064 and 0.12 
respectively, compared to a background population risk of about 0.01. However these values 
for the DD/ASD/CM phenotypes were 0.26 and 0.88. In general it seems that these CNVs 
produce a substantial risk of some kind of developmental abnormality but that schizophrenia 
represents only one possible outcome. Although their effect sizes are large, overall they 
remain a rare cause of schizophrenia and together are found in only 2-3% of cases. 
Overlap with developmental disorders 
Studies of dURVs, LoF variants affecting SETD1A and CNVs all demonstrate that disruption 
of the same genes can lead to either schizophrenia or a different neurodevelopmental 
disorder (Genovese et al. 2016; Singh et al. 2016; Kirov et al. 2014). To investigate this 
issue further, a meta-analysis was carried out using SNV calls from the whole-exome 
sequences of 4,133 schizophrenia cases and 9,274 matched controls, de novo mutations 
identified in 1,077 schizophrenia parent–proband trios and CNV calls from genotyping array 
data of 6,882 cases and 11,255 controls (Singh et al. 2017). This study showed that in 
schizophrenia cases there was an enrichment for rare, damaging variants in LoF-intolerant 
genes but that the effect size was smaller than for ASD and severe developmental disorders. 
Similar genes were involved, in that genes implicated in ASD and severe developmental 
disorders were significantly enriched for rare, damaging variants in schizophrenia cases (p = 
9.5 x 10-6 and 2.3 x 10-6 respectively). The authors were able to acquire the cognitive 
phenotype for 2,971 schizophrenia cases, of whom 279 were also diagnosed with intellectual 
disability (ID). In this group of 279 SCZ-ID cases, the burden of rare, damaging variants in 
LoF-intolerant genes was observed to be significantly higher than in the other schizophrenia 
cases (OR =1.3, p = 2.6 x 10-4) or in controls (OR = 1.61, p < 5 x 10-7). Likewise, these SCZ-
ID cases also had a significant enrichment of rare LoF variants in developmental disorder–
associated genes as compared to the other schizophrenia cases (OR=2.4, P = 9 × 10−4) or 
to controls (OR = 3.4, P = 9.5 × 10−6). Schizophrenia cases without ID did not have this 
enrichment in neurodevelopmental disorder–associated genes but did still have some 
enrichment of rare, damaging variants in LoF intolerant genes relative to controls (OR=1.3, P 
= 2 × 10−6). Overall, these analyses demonstrated that the burden of rare, damaging variants 
is highest in subjects with schizophrenia who also have lower cognitive functioning and that 
these subjects account at least in part for the observed sharing of rare genetic risk factors 
between schizophrenia and other neurodevelopmental disorders. 
Conclusion 
Studies of common variants demonstrate that they do modify risk of schizophrenia but have 
not been able to implicate individual genes. No variant has an individually large effect, as is 
to be expected given the selection pressures which result from the impaired reproductive 
fitness associated with schizophrenia (Power et al. 2013). By contrast, extremely rare CNVs 
and LoF variants, sometimes affecting individual genes, can result in a high risk of 
schizophrenia, as is the case for NRXN1, SETD1A and RBM12. The findings for NRXN1 and 
C4 point to specific biological processes but otherwise it is difficult to say more than that the 
evidence seems to point towards genes involved in neurodevelopment and genes whose 
products are located in synapses. As further sequence data becomes available for analysis it 
is reasonable to expect that additional rare variants in additional genes may be recognised 
and that these may lead on to a better understanding of pathogenesis. 
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